A total of 18 countries participated in the study. Resistance was highest in Southern Italy (approximately 40%), Croatia, and Greece (35% and 30% respectively). This was presumably attributable to the overuse of antibiotics for common viral infections. This was aggravated by the lack of cooperation by medical institutions when it comes to limiting the use of antibiotics. These findings support data that both Italy and Greece have the highest mortality rates for antibiotic resistance among EU member countries.
Comparable rates of antibiotic resistance were found in Poland, Bulgaria, Ireland, Austria, France, and Germany. Nations with the lowest rates of resistance include Denmark, at just 5%, Latvia, with about 7%, and Norway and the Netherlands, at about 9% each.
If H. pylori infection is not controlled due to rising antibiotic resistance rates, gastric cancer rates are likely to increase in conjunction with increasing rates of gastric ulcer. Explaining the situation, Prof. Megraud said, “With resistance rates to commonly used antibiotics such as clarithromycin increasing at an alarming rate of nearly 1% per year, treatment options for H. pylori will become progressively limited and ineffective if novel treatment strategies remain undeveloped.”
- Megraud, F et al. European survey of Helicobacter pylori primary resistance to antibiotics - Evolution over the last 20 years. UEG Week Barcelona, Catalonia, Spain, October 19-23, 2019, Abstract OP035.
Posted on
Previous Article
« ESC guidelines on chronic coronary syndromes focus on lifestyle Next Article
IBD prevalence 3 times higher than estimated and expected to rise »
« ESC guidelines on chronic coronary syndromes focus on lifestyle Next Article
IBD prevalence 3 times higher than estimated and expected to rise »
Table of Contents: UEGW 2019
Featured articles
Interview with UEG President Prof. Paul Fockens
Upper GI Disorders
Locally active corticosteroid promising in eosinophilic oesophagitis
First-in-human radiofrequency vapor ablation in Barrett’s oesophagus
Irritable Bowel Syndrome
Faecal microbiota transplantation is effective for irritable bowel syndrome
Human milk oligosaccharides improve IBS symptoms
Inflammatory Bowel Disease
Ustekinumab is safe and effective in ulcerative colitis: 2-year data
Decreased microvilli length in CD patients
Phase 2 data shows benefit for mirikizumab in CD patients
Subcutaneous ustekinumab as maintenance therapy in UC
First evidence of long-term efficacy of ABX464 in ulcerative colitis
New treatment may reverse coeliac disease
IBD prevalence 3 times higher than estimated and expected to rise
Microbiome and Microbiota
Early stages of gastric metaplasia: molecular profiling
Plant-based foods and Mediterranean diet associated with healthy gut microbiome
Antibiotic resistance in H. pylori has doubled over last 20 years
Pancreatitis
New model predicts recurrence of acute biliary pancreatitis
Hepatology
Restrictive strategy for cholecystectomy selection does not reduce pain, but does reduce surgery
β-blockers may halt cirrhosis progression: PREDESCI trial
Obeticholic acid prevents liver fibrosis from NASH
Oncology
Metal stents are better than plastic for endoscopic biliary drainage
Ramosetron relieves low anterior resection syndrome
Immunonutrition during neoadjuvant oesophagogastric cancer therapy: no benefit
Endoscopy
EUS-guided histological specimens from the pancreatic cyst wall
Digital single-operator cholangioscopy more sensitive than endoscopic retrograde cholangiopancreatography
New single-use duodenoscope well-liked by endoscopists
Related Articles
October 23, 2019
Global burden of digestive diseases reveals alarming trends
October 23, 2019
First evidence of long-term efficacy of ABX464 in ulcerative colitis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy